ClinicalTrials.gg
Active, not recruitingNCT05996471EMBRACEUpdated Nov 5, 2026

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

A Phase 2 interventional study of VH3810109 and Cabotegravir in HIV Infections, sponsored by ViiV Healthcare. Active, not recruiting at 45 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Updated Nov 5, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
185
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Enrollment
71st of 210
185 · median 82
Started
2023
with 9 others
Phase 2
48 of 266
2 open now
Primary completion
2026-05
later than 7 of 26 live
Registered
237th of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 71st largest by enrollment of the 210 interventional ones that give a count, is one of 10 that started in 2023, is one of 48 in phase 2, reaches primary completion later than 7 of the 26 other live ones, and was the 237th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The study aims at evaluating the efficacy of VH3810109, dosed in accordance with the dosing schedule as either intravenous (IV) infusion or subcutaneous (SC) infusion with recombinant hyaluronidase (rHuPH20), in combination with cabotegravir (CAB) intramuscular (IM) dosed in accordance with the dosing schedule in virologically suppressed, Antiretroviral therapy (ART)-experienced adult participants living with HIV. VH3810109 plus rHuPH20 plus Cabotegravir arm of the study has been discontinued based on preliminary results. The study will be conducted in 3 parts followed by a Long-Term Follow-up phase (LTFU).

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • VH3810109
  • Cabotegravir
  • Standard of care
  • HIV
  • Long acting
  • Virologically Suppressed
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age

  1. Participant must be 18 to 70 years of age inclusive, at the time of signing the .

    Type of Participant and Disease Characteristics

  2. Must be on uninterrupted current regimen for at least 6 months prior to Screening. Any prior switch, defined as a change of a single drug or multiple drugs simultaneously, must have occurred due to tolerability/safety, access to medications, or convenience/simplification, and must NOT have been done for treatment failure (-1 RNA ≥200 c/mL).

    Acceptable stable - ARV regimens prior to Screening include at least one NRTI plus:

    • INSTI
    • NNRTI
    • Boosted PI (or atazanavir [ATV] unboosted)
    • Excludes current use of cabotegravir or fostemsavir

    The addition, removal, or switch of a drug(s) that has been used to treat HIV based on antiretroviral properties of the drug constitutes a change in ART with the following limited exceptions:

    • Historical changes in formulations of ART drugs or booster drugs will not constitute a change in ART regimen if the data support similar exposures and efficacy, and the change must have been at least 3 months prior to Screening.
    • Historical maternal perinatal use of an NRTI when given in addition to an ongoing HAART will not be considered a change in ART regimen.
    • A change in dosing scheme of the same drug from twice daily to once daily will not be considered a change in ART regimen if data support similar exposures and efficacy.

    For Part 2

    • Any participant who has received or is currently receiving an INSTI at the time of screening must be on their first INSTI-containing regimen and must not have used any other INSTIs previously
  3. Documented evidence of at least two plasma HIV-1 RNA measurements \<50 c/mL in the 12 months prior to Screening: one within the 6 to 12-month window, and one within 6 months prior to Screening;
  4. Plasma HIV-1 RNA \<50 c/mL at Screening;
  5. Screening ≥350 cells/mm3:

    Weight

  6. Body weight >=50 kg to \<=115 kg.

    Sex

  7. Male and/or female use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies, assuring minimal contraception requirements noted below.

All participants participating in the study should be counselled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g. male condom) and on the risk of HIV transmission to an uninfected partner.

  1. Participants who are female at birth are eligible to participate if at least one of the following conditions applies:

    • Not pregnant or breastfeeding and at least one of the following conditions applies:

      • Is not a participant of (POCBP). OR
      • Is a POCBP and using an acceptable contraceptive method during the intervention period (at a minimum until after the last dose of study intervention). The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
    • A POCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) on Day 1, prior to the first dose of study intervention.

      • If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
    • The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a POCBP with an early undetected pregnancy.

    8. QTc Interval \<450 msec.

    Phenotypic Sensitivity 9. Viral phenotypic sensitivity to VH3810109 based on IC90 of \<=2 ug/mL and a Maximum Percent Inhibition >98% using the Monogram PhenoSense mAb Assay on sample obtained at a screening visit.

    Informed Consent 10. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Exclusion Criteria:

Medical conditions:

  • Participants who are pregnant, breastfeeding, plan to become pregnant or breastfeed during the study
  • Participants having skin disease or disorder (i.e. infection, inflammation, dermatitis, eczema, drug rash, drug allergy, psoriasis, food allergy, urticaria) or tattoo overlying potential injection sites which may interfere with interpretation of injection site reactions or administration of VH3810109 or CAB
  • Participant has a gluteal implant/enhancement (including fillers) overlying the gluteus area or any other area which may significantly interfere with interpretation of injection site reactions
  • Participants with known history of cirrhosis with or without viral hepatitis co-infection
  • Participants with ongoing or pancreatitis
  • Untreated syphilis infection (positive rapid plasma reagin (RPR) at screening) without documentation of treatment. Participants who are at least 7 days post completed treatment are eligible if recruitment is open
  • Prior receipt of licensed or monoclonal antibody
  • Any evidence of an active Centers for Disease Control and Prevention (CDC) Stage 3 disease except cutaneous Kaposi's sarcoma not requiring systemic therapy. Historical or current less than 200 cells/mm\^3 are not exclusionary
  • History of sensitivity to any of the study medications or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation
  • Any condition which, in the opinion of the investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs, cART or render the participant unable to take oral medication
  • Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening
  • Previous exposure to cabotegravir
  • Participant enrolled in a prior or concurrent clinical study that includes a drug intervention within the last 30 days
  • Participants with chronic (HBsAg positive) infection
  • Individuals who are co-infected with HIV and Hepatitis B virus (HBV) will be excluded.
  • Participants with co-infection
  • Unstable liver disease (as defined by any of the following: presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice or cirrhosis), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment).
  • Participants who in the investigator's judgment, pose a significant suicidality risk
  • , as per the current Prescribing Information for cabotegravir.
  • Previous reaction to cabotegravir or
  • Contraindicated co-administered drugs:

    • Anticonvulsants: Carbamazepine, oxcarbazepine, phenobarbital, phenytoin
    • Antimycobacterials: Rifabutin, rifampin, rifapentine
    • (systemic): Dexamethasone (more than a single-dose treatment)
    • Herbal product: St John's wort (Hypericum perforatum)

Prior/Concomitant Therapy:

  • Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.
  • Previous exposure to cabotegravir.
  • Treatment with any of the following agents within 60 days of screening:

    -radiation therapy;

    • cytotoxic chemotherapeutic agents;
    • any systemic immune suppressant.
  • Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of study medication.
  • Current or anticipated need for chronic anti-coagulants.
  • Participants receiving any prohibited medication and who are unwilling or unable to switch to an alternate medication.

Prior/Concurrent Clinical Study Experience • Participant enrolled in a prior or concurrent clinical study that includes a drug intervention within the last 30 days.

Diagnostic Assessments • Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the participants inclusion in the study of an investigational compound.

  • Any evidence of viral resistance based on the presence of any major cabotegravir resistance-associated mutation [IAS-USA, 2022] in any historic resistance test result.
  • Any verified Grade 4 laboratory abnormality with the exception of Grade 4 triglycerides or lipid abnormalities. A single repeat test is allowed during the Screening period to verify a result.
  • (ALT) >=3 times the (ULN)
  • of \<50 mL/min/1.73 m\^2 via using the refitted, race-neutral Chronic Kidney Disease Epidemiology Collaboration (CKD-EPIcr_R) method.
  • PT >=Grade 2 (>=1.25 ULN). A single repeat test is allowed during the Screening period to verify a result.

Other Exclusion Criteria

  • To assess any potential impact on participant eligibility with regard to safety, the investigator must refer to the IB and supplements, approved product labels, and/or local prescribing information for detailed information regarding warnings, precautions, contraindications, AEs, drug interactions, and other significant data pertaining to the study drugs.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
185 participants (actual)

Study arms

  • Experimental
    Part 1A: Participants Receiving VH3810109 Formulation 1 plus Cabotegravir

    Participants will receive VH3810109 formulation 1 intravenously (IV) and Cabotegravir intramuscularly (IM) every month (QM). Participants from this arm will either transition to Part 2A or discontinue from the study and enter the LTFU period.

    Biological: VH3810109 · Drug: Cabotegravir

  • Experimental
    Part 1B: Participants Receiving VH3810109 plus rHuPH20 plus Cabotegravir

    Participants will receive VH3810109 plus rHuPH20 via subcutaneous (SC) infusion and Cabotegravir IM. This arm was discontinued following preliminary results. Participants from this arm will either transition to Part 1A at the next dosing visit or withdraw from the Investigational Product (IP) and enter the LTFU.

    Biological: VH3810109 · Drug: Cabotegravir · Biological: rHuPH20

  • Active comparator
    Part 1C: Participants Receiving SOC ART

    Participants in this arm will either transition to Part 2B or Part 2C or discontinue from the study.

    Drug: Standard of care (SOC)

  • Experimental
    Part 2A: Participants Receiving VH3810109 Formulation 2 plus Cabotegravir Q2M

    Participants will receive VH3810109 formulation 2 intravenously (IV) and Cabotegravir intramuscularly (IM) every 2 months (Q2M). Participants from this arm will either transition to Part 3A or discontinue from the study and enter the LTFU period.

    Biological: VH3810109 · Drug: Cabotegravir

  • Experimental
    Part 2B: Participants Receiving VH3810109 Formulation 2 plus Cabotegravir

    Participants will receive VH3810109 formulation 2 intravenously (IV) and Cabotegravir intramuscularly (IM) at Day 1, Month 1, Month 2 and then Q2M. Participants from this arm will either transition to Part 3A or discontinue from the study and enter the LTFU period.

    Biological: VH3810109 · Drug: Cabotegravir

  • Active comparator
    Part 2C: Participants continuing SOC ART

    Participants in this arm will either transition to Part 3B or discontinue from the study.

    Drug: Standard of care (SOC)

  • Experimental
    Part 3A: Participants continuing VH3810109 Formulation 2 plus Cabotegravir Q2M

    Participants will continue to receive VH3810109 formulation 2 intravenously (IV) and Cabotegravir intramuscularly (IM) every 2 months (Q2M).

    Biological: VH3810109 · Drug: Cabotegravir

  • Experimental
    Part 3B: Participants receiving VH3810109 Formulation 2 plus Cabotegravir

    Participants will receive VH3810109 formulation 2 intravenously (IV) and Cabotegravir intramuscularly (IM) at Day 1, Month 1, Month 2 and then Q2M.

    Biological: VH3810109 · Drug: Cabotegravir

Interventions

  • BiologicalVH3810109

    VH3810109 will be administered.

  • Cabotegravir will be administered.

  • DrugStandard of care (SOC)

    Pre-baseline SOC antiretroviral therapy (ART) will be administered.

  • BiologicalrHuPH20

    rHuPH20 will be administered.

06

What researchers measure

Primary outcomes

  1. Part 1 and Part 2B and 2C: Number of Participants with Plasma HIV-1 Ribonucleic acid (RNA) Greater Than or Equal to (≥)50 Copies per Millilitre (c/mL) per Snapshot Algorithm at Month 6

    Time frame: Month 6

Secondary outcomes

  1. Part 1, 2 and 3: Number of Participants with Serious Adverse Events (SAEs), Deaths, and Adverse Events (AEs) Leading to Discontinuation of Investigational Product (IP)

    Time frame: Up to Month 24

  2. Part 1, 2 and 3: Number of Participants with Grade 3-4 AEs

    Time frame: Up to Month 24

  3. Part 1, 2 and 3: Number of Participants with Grade 3-4 Laboratory Abnormalities

    Time frame: Up to Month 24

  4. Part 1, 2 and 3: Number of Participants with Grade 1-4 Injection/infusion Site Reactions

    Time frame: Up to Month 24

  5. Part 1, 2 and 3: Number of Participants Meeting Confirmed Virologic Failure (CVF) Criteria over time

    Time frame: Up to Month 24

  6. Part 1, 2 and 3: Number of Participants with Plasma HIV-1 RNA ≥50 c/mL per Snapshot Algorithm Over Time

    Time frame: Up to Month 24

  7. Part 1, 2 and 3: Number of Participants with Plasma HIV-1 RNA Less Than (<)50 c/mL per Snapshot Algorithm Over Time

    Time frame: Up to Month 24

  8. Part 1, 2 and 3: Number of Participants with HIV Disease Progression

    Time frame: Up to Month 24

  9. Part 1, 2 and 3: Serum Concentrations of VH3810109

    Time frame: Up to Month 24

  10. Part 1, 2 and 3: Plasma Concentrations of Cabotegravir

    Time frame: Up to Month 24

  11. Part 1, 2 and 3: Absolute Value for Cluster of Differentiation 4 (CD4+) T-Cell Count

    Time frame: Up to Month 24

  12. Part 1, 2 and 3: Change from Baseline in CD4+ T-Cell Count

    Time frame: Baseline (Day 1) and up to Month 24

  13. Part 1, 2 and 3: Absolute Value for Cluster of Differentiation 8 (CD8+) T-Cell Count

    Time frame: Up to Month 24

  14. Part 1, 2 and 3: Change from Baseline in CD8+ T-Cell Count

    Time frame: Baseline (Day 1) up to Month 24

  15. Part 1, 2 and 3: Number of Participants with Anti-VH3810109 Antibodies

    Time frame: Up to Month 24

  16. Part 1, 2 and 3: Number of Participants with Neutralizing Antibodies Against VH3810109

    Time frame: Up to Month 24

  17. Part 1, 2 and 3: Number of Participants with Treatment-emergent Genotypic Resistance

    Time frame: Up to Month 24

  18. Part 1, 2 and 3: Number of Participants with Treatment-emergent Phenotypic Resistance

    Time frame: Up to Month 24

07

Study locations

45 sites
  • GSK Investigational Site
    Birmingham, Alabama 35222, United States
  • GSK Investigational Site
    Bakersfield, California 93309, United States
  • GSK Investigational Site
    Los Angeles, California 90027, United States
  • GSK Investigational Site
    Los Angeles, California 90069, United States
  • GSK Investigational Site
    Palm Springs, California 92262, United States
  • GSK Investigational Site
    Sacramento, California 95825-2115, United States
  • GSK Investigational Site
    San Francisco, California 94110, United States
  • GSK Investigational Site
    New Haven, Connecticut 06510, United States
  • GSK Investigational Site
    Washington D.C., District of Columbia 20007-2113, United States
  • GSK Investigational Site
    Washington D.C., District of Columbia 20037, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • GSK Investigational Site
    Ft. Pierce, Florida 34982-7148, United States
  • GSK Investigational Site
    Miami, Florida 33133, United States
  • GSK Investigational Site
    Orlando, Florida 32803-1851, United States
  • GSK Investigational Site
    Pensacola, Florida 32503, United States
  • GSK Investigational Site
    Sarasota, Florida 34237-3116, United States
  • GSK Investigational Site
    Vero Beach, Florida 32960-6541, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33409, United States
  • GSK Investigational Site
    Decatur, Georgia 30033, United States
  • GSK Investigational Site
    Chicago, Illinois 60611-2826, United States
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
  • GSK Investigational Site
    Springfield, Massachusetts 01105, United States
  • GSK Investigational Site
    Southfield, Michigan 48075, United States
  • GSK Investigational Site
    Columbia, Missouri 65212, United States
  • GSK Investigational Site
    Newark, New Jersey 07102, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87109, United States
  • GSK Investigational Site
    Santa Fe, New Mexico 87505-4753, United States
  • GSK Investigational Site
    Manhasset, New York 11030, United States
  • GSK Investigational Site
    New York, New York 10029, United States
  • GSK Investigational Site
    New York, New York 10032, United States
  • GSK Investigational Site
    The Bronx, New York 10461-1119, United States
  • GSK Investigational Site
    The Bronx, New York 10467, United States
  • GSK Investigational Site
    Greensboro, North Carolina 27401-1209, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45267, United States
  • GSK Investigational Site
    Portland, Oregon 97239-3011, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    Nashville, Tennessee 37208, United States
  • GSK Investigational Site
    Austin, Texas 78705-3326, United States
  • GSK Investigational Site
    Dallas, Texas 75246-2004, United States
  • GSK Investigational Site
    El Paso, Texas 79902, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Houston, Texas 77098, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53226-3548, United States
  • GSK Investigational Site
    San Juan, 00909, Puerto Rico
  • GSK Investigational Site
    San Juan, 909, Puerto Rico
08

References and documents

Publications

  • Leone PA, Losos J, Wannamaker P, D'Agostino R, Warwick-Sanders M, Ghita GL, Wilches V, Donatti C, Brown K, Gandhi Y. VH3810109 (N6LS) broadly neutralizing antibody safety, pharmacokinetics, and anti-drug antibody incidence in adults without HIV: phase 1 SPAN study results. Antimicrob Agents Chemother. 2025 Sep 3;69(9):e0025825. doi: 10.1128/aac.00258-25. Epub 2025 Jul 23. PubMed 40698814 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in May 2026, 33 months.

Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 33 months is above that.

Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2023
First posted
Aug 18, 2023
StartActual
Aug 17, 2023
Primary completionActual
May 27, 2026
CompletionEst.
Nov 9, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • GSK Investigational Site · The Bronx, United States
Show 1 removed
  • GSK Investigational Site · New York, United States
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    1 site added, 1 site removed
    Show site
    • GSK Investigational Site · The Bronx, United States
    Show 1 removed
    • GSK Investigational Site · New York, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05996471
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Aug 18, 2023
Start date
Aug 17, 2023
Primary completion
May 27, 2026
Completion
Nov 9, 2028 (estimated)
Last update
Nov 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: VH3810109 · Hyaluronidase (human recombinant)

Start the discussion